Fourrts (India) Laboratories P. Ltd Vs Commissioner of GST & Central Excise (CESTAT Chennai)
Introduction: In a significant judgment, the CESTAT Chennai weighed in on the debate over the appropriate assessment of physician samples, rendering its decision in favor of Fourrts (India) Laboratories P. Ltd. This article provides an in-depth analysis of the ruling and its implications.
Background and Contention: Upon examination of Fourrts India’s records, discrepancies were noted in their product clearances. For sales, they used valuation under Section 4A of the Central Excise Act, 1944. However, for physician samples, they adopted the transaction value as per Section 4. The department believed that physician samples should also be evaluated under Section 4A. Consequently, a Show Cause Notice was issued for the differential duty, interest, and penalties. Both the original authority and Commissioner (Appeals) sided with the department, which led to this appeal.
Arguments Presented:
1. Appellant’s Standpoint: Ms. Manne Veera Niveditha, the advocate for Fourrts India, referenced previous judgments from the Hon’ble Apex Court, highlighting that Sections 4 and 4A are distinct and driven by separate legal principles. She emphasized the inapplicability of Rule 4 of the Central Excise Valuation Rules 2000 to Section 4A, arguing that the basis for demand was fundamentally flawed.
2. Department’s Perspective: The Learned AR Shri Sathyanarayanan, Assistant Commissioner (AR), bolstered the initial findings, leading to a pivotal discussion on the correct assessment of physician samples.
Key Discussion Points:
The core issue under scrutiny was whether physician samples should fall under Section 4 (1) (a) or 4 (1) (b) of the Central Excise Act, 1944. The Hon’ble Apex Court’s previous decision in the case of Sun Pharmaceuticals Ltd. was cited, highlighting:
